Fulranumab

N/A

Report date: 2024/12/18 10:01:30

Base Information

Drug NameFulranumab
Drug Alias NameFulranumabum福拉奴单抗伏雷努单抗JNJ-42160443AMG-403
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionNerve growth factor receptors antagonists
TargetsNerve growth factor receptors
Therapy Area/IndicationsChronic PainLow Back PainPain +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[16] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAmgen IncJanssen Research & Development LlcJohnson & Johnson Pharmaceutical Research & Development LLC
Active IndicationsN/A
Inactive IndicationsChronic PainLow Back PainPain +[15] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG